J Clin Endocrinol Metab 93:2948–2952CrossRefPubMed 40 Kwek EB, K

J Clin Endocrinol Metab 93:2948–2952CrossRefPubMed 40. Kwek EB, Koh JS, Howe TS (2008) More on atypical fractures of the femoral diaphysis. N Engl J Med 359:316–317CrossRefPubMed 41. Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306CrossRefPubMed 42. Leung F, Lau T-W, To M, Luk K-K, Kung A (2010) Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates. BMJ Case Reports. doi:10.​1136/​bcr.​10.​2008.​1073 43. Brandser EA, Buckwalter JA (1996) Imaging this website studies for diagnosing stress and

insufficiency fractures. Iowa Orthop J 16:70–78PubMed 44. Lunsjo K, Ceder L, Tidermark J, Hamberg P, Larsson BE, Ragnarsson B, Knebel RW, Allvin I, Hjalmars K, Norberg S, Fornander P, Hauggaard A, Stigsson L (1999) Extramedullary fixation of 107 subtrochanteric fractures: a randomized multicenter trial of the Medoff sliding plate versus 3 other screw-plate systems. Acta Orthop Scand 70:459–466CrossRefPubMed 45. Whitelaw GP, Segal D, Sanzone CF, Ober NS, Hadley N (1990) Unstable intertrochanteric/subtrochanteric fractures

of the femur. Clin Orthop Relat Res 252:238–245PubMed 46. Nieves JW, Bilezikian CHIR-99021 supplier JP, Lane JM, Einhorn TA, Wang Y, Steinbuch M, Cosman F (2010) Fragility fractures of the hip and femur: incidence and patient 3-mercaptopyruvate sulfurtransferase characteristics. Osteoporos Int 21:299–408CrossRef 47. Glennon DA (2009) Subtrochanteric stress fractures in six patients on long term bisphosphonate therapy: a case series. Bone 44:S68–S98CrossRef 48. National Institute for Health and Clinical Excellence (2010) Final appraisal

determination. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (amended). NICE technology appraisal guidance 160 (amended). http://​www.​nice.​org.​uk/​nicemedia/​pdf/​TA160guidance.​pdf. Accessed 23 Sep 2010 49. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–CDK inhibitor drugs 1733CrossRefPubMed 50. Giusti A, Hamdy NA, Papapoulos SE (2010) Atypical fractures of the femur and bisphosphonate therapy. A systematic review of case/case series studies. Bone 47:169–180CrossRefPubMed 51. Husada G, Libberecht K, Peeters T, Populaire J (2005) Bilateral mid-diaphyseal femoral stress fractures in the elderly. Eur J Trauma 31:68–71CrossRef 52. Schneider JP (2006) Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 61:31–33PubMed 53. Armamento-Villareal R, Napoli N, Panwar V, Novack D (2006) Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 355:2048–2050CrossRefPubMed 54.

Comments are closed.